Interest in medical research has reached an unprecedented level in recent years. This increase in interest, combined with recognition of the benefits afforded by research, has provided an impetus to increase funding for medical research to 10 to 15 percent of the annual federal budget. In the context of economic recession and competing demands on available funds, What Price Better Health? Hazards of the Research Imperative, by Daniel Callahan, highlights important ethical considerations, including the nature of our research agenda, priorities for research goals, the manner in which research funding is allocated, collaborative efforts of public and private sectors, the difficulties and paucity of good risk-benefit analysis, and the moral challenge of controversial research agendas, such as stem cell research or research in developing countries. Callahan challenges us to consider research within the context of other social and economic needs and to move beyond the desire to prolong life, defy death, and eradicate disease.